Moderna (MRNA) Stock Forecast & Price Target

$79.83

+2.13 (+2.74%)

(As of 12/1/2023 ET)

Today's Range: $74.50
▼
$80.26
50-Day Range: $69.51
▼
$104.43
52-Week Range: $62.55
▼
$217.25

Volume: 3.88 million shs
Average Volume: 3.71 million shs
Market Capitalization: $30.44 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $133.70

Moderna Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 20 Analyst Ratings

Analysts' Consensus Price Target

$133.70
67.48% Upside

High Forecast	$231.00
Average Forecast	$133.70
Low Forecast	$60.00

Type	Current Forecast 12/2/22 to 12/2/23	1 Month Ago 11/2/22 to 11/2/23	3 Months Ago 9/3/22 to 9/3/23	1 Year Ago 12/2/21 to 12/2/22
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	11 Hold rating(s)	8 Hold rating(s)	9 Hold rating(s)	7 Hold rating(s)
Sell	3 Sell rating(s)	4 Sell rating(s)	3 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$133.70	$143.33	$156.07	$176.93
Predicted Upside	67.48% Upside	5.04% Upside	12.22% Upside	19.37% Upside

Get Moderna Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.

MRNA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Moderna Stock vs. The Competition

Type	Moderna	Medical Companies	S&P 500
Consensus Rating Score	2.15	2.67	2.49
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	67.48% Upside	759.83% Upside	2,867.39% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/1/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$93.00 ➝ $90.00	+13.92%
11/29/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$82.00	+4.89%
11/3/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$180.00 ➝ $125.00	+60.32%
11/3/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$269.00 ➝ $231.00	+198.22%
11/3/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$89.00 ➝ $69.00	-3.13%
11/2/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Hold ➝ Sell	$125.00 ➝ $60.00	-21.26%
Get the Latest News and Ratings for MRNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.
9/13/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$160.00 ➝ $140.00	+26.96%
8/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$128.00 ➝ $123.00	+13.37%
8/4/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$275.00 ➝ $175.00	+59.90%
8/4/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$175.00 ➝ $150.00	+37.06%
8/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$145.00 ➝ $125.00	+13.69%
7/24/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$136.28	+7.79%
6/26/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Upgrade
6/26/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$221.00 ➝ $191.00	+61.18%
4/25/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
2/24/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Foroohar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform	$111.00 ➝ $93.00	-33.95%
2/24/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$111.00 ➝ $93.00	-36.98%
1/25/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$130.00 ➝ $150.00	-23.76%
1/18/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Livshits Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral	$191.00 ➝ $208.00	+4.17%
12/20/2022	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$214.00 ➝ $217.00	+14.28%

(Data available from 12/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

MRNA Price Target - Frequently Asked Questions

What is Moderna's consensus rating and price target?: According to the issued ratings of 20 analysts in the last year, the consensus rating for Moderna stock is Hold based on the current 3 sell ratings, 11 hold ratings and 6 buy ratings for MRNA. The average twelve-month price prediction for Moderna is $133.70 with a high price target of $231.00 and a low price target of $60.00. Learn more on MRNA's analyst rating history.
Do Wall Street analysts like Moderna more than its competitors?: Analysts like Moderna less than other Medical companies. The consensus rating for Moderna is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how MRNA compares to other companies.
Is Moderna being upgraded or downgraded by Wall Street analysts?: Over the previous 90 days, Moderna's stock had 1 upgrade and 1 downgrade by analysts.

Does Moderna's stock price have much upside?: According to analysts, Moderna's stock has a predicted upside of 13.03% based on their 12-month stock forecasts.
What analysts cover Moderna?: Moderna has been rated by Argus, Canaccord Genuity Group, Canaccord Genuity Group, Deutsche Bank Aktiengesellschaft, HSBC, JPMorgan Chase & Co., Royal Bank of Canada, and The Goldman Sachs Group in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:MRNA) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial